drugset / Trial / NCT05797506
Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease
Phase 2
Completed
96 enrolled
University of Rochester
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNutramax Laboratories, Inc. · collabUniversity of Virginia · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The Sulforaphane Production System® in Avmacol Extra Strength (ES) supplies broccoli seed extract (glucoraphanin) and Myrosimax® (Active Myrosinase Enzyme) which helps promote sulforaphane production in your body. The investigators hypothesize that daily intake of Avmacol ES can decrease kidney disease progression rate and decrease markers of oxidative stress and inflammation in Chronic Kidney Disease (CKD) patients. They will test this hypothesis in a randomized, double-blind, placebo controlled Phase 2 clinical trial. This proposed study has been funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), R01 DK128677.
Timeline
- Start
- 2023-05-03
- Primary completion
- 2025-04-25
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sulforaphane | Small molecule | 4 unknown | — |